These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36822884)

  • 1. A Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Tacrolimus and Corticosteroids in Combination With or Without Mycophenolate Mofetil in Liver Transplantation Recipients Infected With Hepatitis B Virus.
    Park JI; Song GW; Ryu JH; Choi ST; Choi NG; Jung BH; Chu CW; Kim KK; Jung DH; Ha TY; Moon DB; Yang K; Shin MH; Chung YK; Hwang S; Yoon YI; Lee SG
    Transplant Proc; 2023 Mar; 55(2):387-395. PubMed ID: 36822884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
    Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a phase 4 trial of Tacrobell® in liver transplantation patients: a multicenter study in South Korea.
    Yu YD; Lee SG; Joh JW; Kwon CH; Kim DG; Suh KS; Lee NJ; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH
    Hepatogastroenterology; 2012; 59(114):357-63. PubMed ID: 21940371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
    Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
    Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.
    Lan X; Liu MG; Chen HX; Liu HM; Zeng W; Wei D; Chen P
    World J Gastroenterol; 2014 Sep; 20(34):12330-40. PubMed ID: 25232269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
    Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
    Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Mycophenolate Mofetil Suspension as Part of Induction Therapy After Living-Donor Liver Transplant.
    Harada N; Yoshizumi T; Yoshiya S; Takeishi K; Toshima T; Itoh S; Ikegami T; Fukuda M; Masuda S; Mori M
    Exp Clin Transplant; 2020 Aug; 18(4):485-490. PubMed ID: 32490763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.